Preclinical studies are the laboratory and animal tests a new drug must pass before it can be tried in humans. Their primary goal is to determine whether a compound is reasonably safe and shows enough biological activity to justify testing in people. This phase lasts about 31 months on average and produces the safety data a company needs to apply for permission to begin human clinical trials.
Where Preclinical Studies Fit in Drug Development
Drug development follows a rough sequence: discovery, preclinical testing, clinical trials (phases 1 through 3), and regulatory review. Preclinical research sits between the moment scientists identify a promising compound and the moment that compound first enters a human body. Everything learned in this stage feeds into an Investigational New Drug (IND) application submitted to the FDA. That application must include animal safety and toxicology data, manufacturing details, and a protocol for the proposed human trials. If the FDA finds the preclinical evidence adequate, the drug advances to Phase 1 clinical testing in a small group of volunteers.
Lab Testing vs. Animal Testing
Preclinical work happens in two main settings. The first is outside a living organism, in test tubes, petri dishes, or cell cultures grown in a lab. Scientists use these experiments to see whether a compound interacts with a target the way they expect, whether it kills cancer cells in a dish, or whether it shows any obvious signs of toxicity at the cellular level. These experiments are relatively fast and inexpensive, and they help narrow down which compounds are worth studying further.
The second setting is inside a living animal, most commonly mice, rats, or dogs. Animal studies reveal things cell cultures cannot: how a drug moves through an intact body, how it affects organs over time, and whether it causes problems at doses that would be relevant to humans. Both types of testing are considered preclinical, though animal studies carry more regulatory weight when it comes to demonstrating safety for human use.
Computer modeling is increasingly used alongside these methods. Simulations can predict how a molecule will behave in the body or flag potential toxicity before any wet-lab work begins, though regulators still require physical testing to back up computational predictions.
What Researchers Measure
Preclinical studies focus on two broad questions: is it safe, and does it do what we think it does?
On the safety side, the central concept is finding the highest dose that produces no significant increase in harmful effects compared to a control group. Researchers call this the “no observed adverse effect level.” Once they identify that threshold in animals, they convert it to a human equivalent dose using body surface area calculations, then divide by a safety factor of at least 10. The result becomes the maximum recommended starting dose for the first human trial. That built-in safety margin is why Phase 1 volunteers typically receive doses far below what would cause harm.
On the effectiveness side, researchers study how the drug behaves inside a living system through four key processes: absorption (how the drug enters the bloodstream), distribution (where it travels in the body), metabolism (how the body chemically transforms it), and excretion (how it leaves). Together, these processes determine practical characteristics like how long the drug stays active, whether food affects its uptake, and which organs are responsible for clearing it. Scientists also measure peak concentration in the blood, how long it takes to reach that peak, and the drug’s half-life, which is how long it takes for the concentration to drop by half.
Quality Standards That Govern the Work
Preclinical safety studies intended for regulatory submission must follow Good Laboratory Practice (GLP) regulations, codified in the U.S. under 21 CFR Part 58. GLP is essentially a quality system designed to ensure that safety data are reliable, reproducible, and detailed enough for someone to reconstruct the study later. It covers everything from how test compounds are handled and stored, to the qualifications and responsibilities of the study director, to how raw data are captured and archived.
A dedicated quality assurance unit inspects studies independently of the people running them. Standard operating procedures govern each step, and the final study report must document methods, results, and any deviations. Labs that fail GLP inspections risk having their data rejected by regulators, which can delay or derail a drug’s path to human testing.
Animal Welfare and the 3Rs
Because animal testing remains necessary for most preclinical programs, ethical guidelines built around three principles shape how that testing is conducted.
- Replacement means using alternatives whenever possible. Full replacement avoids animals entirely through tools like human cell cultures, computer models, or training manikins. Partial replacement uses animal-derived tissues or organisms like zebrafish embryos that do not experience pain or distress.
- Reduction means designing experiments to gather the same quality of information from fewer animals. Better statistical planning and resource sharing between research groups both contribute to this goal.
- Refinement means modifying procedures to minimize pain and distress. This includes using anesthetics and analgesics during procedures, providing environmental enrichments in housing, and establishing humane endpoints so animals are not subjected to suffering beyond what is scientifically necessary.
These principles are not optional suggestions. Institutional review committees evaluate proposed animal studies against 3Rs criteria before approving them, and regulatory agencies expect evidence that researchers have considered alternatives.
Timeline and What Comes Next
The preclinical phase averages about 31 months, considerably shorter than the clinical phase that follows, which averages around 95 months. Despite its shorter duration, preclinical work is where the vast majority of drug candidates fail. A compound might prove too toxic at effective doses, break down too quickly in the body, or simply not produce the expected biological effect in a living system.
Compounds that survive preclinical testing move into Phase 1 clinical trials, where a small number of healthy volunteers receive carefully calculated low doses. The preclinical data don’t just open the door to human testing; they shape every early decision in the clinic, from the starting dose to the monitoring plan to which side effects doctors watch for. A thorough preclinical program reduces the risk that volunteers encounter unexpected harm, which is why regulators hold this stage to such exacting standards.